We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $177M
1-Year Est. Return 91.13%
This Fund
S&P 500
This Quarter Est. Return
+5.68%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.67%
10 Year Est. Return
+2,169.5%
AUM
$177M
AUM Growth
+$9.56M
Cap. Flow
-$11.5M
Cap. Flow %
-6.47%
Top 10 Hldgs %
81.28%
Holding
26
New
3
Increased
10
Reduced
6
Closed
5

Top Buys

Rank Stock Value
1
VIVE
VIVEVE MED INC
VIVE
+$6.08M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.17M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$4.26M
4
SCLN
Sciclone Pharmaceuticals Inc
SCLN
+$4.14M
5
VCEL icon
Vericel Corp
VCEL
+$3.9M

Top Sells

Rank Stock Value
1
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
+$3.85M
2
ALR
Alere Inc
ALR
+$3.32M
3
VCYT icon
Veracyte
VCYT
+$3.21M
4
ALIM
Alimera Sciences
ALIM
+$2.62M
5
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$2.17M

Sector Composition

Rank Sector Weight
1 Healthcare 92.52%
2 Miscellaneous 7.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCTL
1
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$25.1M 14.16%
3,204,863
– –
VIVE
2
DELISTED
VIVEVE MED INC
VIVE
$24.3M 13.67%
3,850
+1,250
+48% +$6.08M
NVLN
3
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$16.8M 9.44%
1,560,487
+36,453
+2% +$373K
SCLN
4
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
$16.3M 9.19%
1,663,281
+414,081
+33% +$4.14M
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$12.9M 7.25%
3,516,489
+1,223,589
+53% +$5.17M
ALR
6
DELISTED
Alere Inc
ALR
$10.9M 6.16%
275,000
-85,000
-24% -$3.32M
VCEL icon
7
Vericel Corp
VCEL
$2.07B
$9.14M 5.15%
3,265,323
+1,381,523
+73% +$3.9M
CORV
8
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$8.3M 4.68%
2,757,260
-401,556
-13% -$1.18M
AVDL
9
DELISTED
Avadel Pharmaceuticals
AVDL
$7.28M 4.1%
752,410
+426,323
+131% +$4.26M
ENTA icon
10
Enanta Pharmaceuticals
ENTA
$408M
$5.7M 3.21%
185,099
-46,814
-20% -$1.46M
BDSI
11
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$5.41M 3.05%
2,844,820
+244,109
+9% +$471K
VCYT icon
12
Veracyte
VCYT
$3.59B
$5.31M 2.99%
578,200
-392,300
-40% -$3.21M
CPIX icon
13
Cumberland Pharmaceuticals
CPIX
$101M
$5.13M 2.89%
739,917
+120,379
+19% +$730K
ALIM
14
DELISTED
Alimera Sciences
ALIM
$3.61M 2.03%
171,752
-135,969
-44% -$2.62M
DRRX
15
DELISTED
DURECT Corp
DRRX
$2.94M 1.66%
280,138
+62,359
+29% +$667K
TRIB
16
Trinity Biotech
TRIB
$7.81M
$2.1M 1.18%
2,346
-561
-19% -$526K
EBS icon
17
Emergent Biosolutions
EBS
$319M
$1.58M 0.89%
+54,505
New +$1.66M
XOMA
18
DELISTED
Xoma
XOMA
$625K 0.35%
+87,960
New +$452K
VNDA icon
19
Vanda Pharmaceuticals
VNDA
$323M
$606K 0.34%
+43,300
New +$617K
VXRT
20
DELISTED
Vaxart
VXRT
$205K 0.12%
28,584
+468
+2% +$4.79K
CUTR
21
DELISTED
Cutera, Inc.
CUTR
– –
-120,429
Closed -$2.09M
MNK
22
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-43,629
Closed -$2.17M
JNP
23
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
– –
-228,392
Closed -$1.28M
SCMP
24
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
– –
-284,002
Closed -$3.85M
CTIC
25
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-261,714
Closed -$1.07M

Similar funds

RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
MSA
Marathon Strategic Advisors Pittsburgh, Pennsylvania $177M AUM 66.85% 1-Year Est. Return
HF
Holcombe Financial Atlanta, Georgia $177M AUM 13.35% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $177M AUM 21.44% 1-Year Est. Return
CWP
Clark Wealth Partners O'fallon, Illinois $177M AUM 22.36% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
CMP
Christine Messmer PC Collegeville, Pennsylvania $177M AUM
JESC
J.E. Simmons & Co Dallas, Texas $177M AUM

Stonepine Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Stonepine Capital Management held 26 positions worth $177M, up 5.7% from $168M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Stonepine Capital Management withdrew a net $11.5M in Q1 2017, closing 5 positions and reducing 6 holdings. Its most notable exit was Sucampo Pharmaceuticals, Inc., an estimated $3.85M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

Against the trend, Stonepine Capital Management opened a new position in Emergent Biosolutions worth $1.58M.

  • Stonepine Capital Management's largest Q1 2017 buy was Emergent Biosolutions: 54,505 shares worth $1.58M.
  • Stonepine Capital Management added most to VIVEVE MED INC in Q1 2017, an estimated $6.08M increase.
  • Stonepine Capital Management's biggest Q1 2017 reduction was Alere Inc, cutting an estimated $3.32M.
  • Stonepine Capital Management fully exited Sucampo Pharmaceuticals, Inc. in Q1 2017, selling an estimated $3.85M.
  • Stonepine Capital Management's ten largest holdings make up 81% of its $177M portfolio in Q1 2017.
  • Stonepine Capital Management opened 3 new positions and closed 5 in Q1 2017.
  • Stonepine Capital Management's portfolio value rose 5.7% quarter-over-quarter to $177M.

Based on Stonepine Capital Management's 13F filing for Q1 2017, filed 12 May 2017.